Want to see AVBP full AI Analyst Report?
Top Page
ArriVent BioPharma, Inc.
(NASDAQ:AVBP)
Select Model
Select Model
Rating:50Neutral
Price Target:
$21.00
▼(-32.56% Downside)
Action:Reiterated
Date:10/24/26
Overall score reflects a strong balance sheet and pipeline activity that help mitigate financing risk, but is weighed down by the lack of revenue, heavy cash burn and widening losses, weak technical trend (below key moving averages with negative MACD), and mixed corporate events highlighted by a Phase 3 miss.
Positive Factors
Strong, lightly levered balance sheet
Extremely low leverage and substantial asset growth provide financial flexibility for continued clinical development. This reduces near-term balance-sheet pressure and supports investment in the pipeline, although the company still needs future revenue or funding to sustain operations over the longer term.
Negative Factors
No revenue and widening losses
ArriVent has not yet established a commercial revenue base to offset its research and development spending. Widening losses increase the distance to self-funded operations and make future financial performance highly dependent on successful clinical development, commercialization or partnership economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong, lightly levered balance sheet
Extremely low leverage and substantial asset growth provide financial flexibility for continued clinical development. This reduces near-term balance-sheet pressure and supports investment in the pipeline, although the company still needs future revenue or funding to sustain operations over the longer term.
Read all positive factors
ArriVent BioPharma, Inc. (AVBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.04B
Dividend YieldN/A
Average Volume (3M)1.78M
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue GrowthN/A
EPS Growth8.22%
CountryUS
Employees77
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.68
Shares Outstanding49,307,728
10 Day Avg. Volume1,448,461
30 Day Avg. Volume1,776,887
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.82
Forecast
1Y Price Target
$26.45Price Target Upside-15.05% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-4.24
Revenue Forecast (FY)N/A
ArriVent BioPharma, Inc. Business Overview & Revenue Model
Company Description
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is ...
ArriVent BioPharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -163.74M | -166.31M | -80.49M | -69.33M | 0.00 | -51.61M |
| Net Income | -163.74M | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
Balance Sheet | ||||||
| Total Assets | 394.72M | 333.17M | 274.94M | 163.10M | 182.83M | 43.04M |
| Cash, Cash Equivalents and Short-Term Investments | 373.12M | 312.82M | 218.86M | 150.39M | 163.37M | 37.28M |
| Total Debt | 351.00K | 14.00K | 176.00K | 317.00K | 139.00K | 0.00 |
| Total Liabilities | 27.88M | 25.95M | 17.29M | 11.80M | 8.37M | 1.82M |
| Stockholders Equity | 366.84M | 307.22M | 257.65M | 151.30M | 174.46M | 41.22M |
Cash Flow | ||||||
| Free Cash Flow | -147.93M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Operating Cash Flow | -147.93M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Investing Cash Flow | -72.31M | -71.23M | -192.47M | 0.00 | 0.00 | -40.00M |
| Financing Cash Flow | 262.15M | 203.06M | 186.58M | 42.86M | 169.72M | 89.87M |
ArriVent BioPharma, Inc. Technical Analysis
Negative
31.14
Price Trends
26.16
Negative
28.95
Negative
27.09
Negative
Market Momentum
-2.41
Negative
46.30
Neutral
92.54
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVBP, the sentiment is Negative. The current price of 31.14 is above the 20-day moving average (MA) of 20.93, above the 50-day MA of 26.16, and above the 200-day MA of 27.09, indicating a neutral trend. The MACD of -2.41 indicates Negative momentum. The RSI at 46.30 is Neutral, neither overbought nor oversold. The STOCH value of 92.54 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVBP.
ArriVent BioPharma, Inc. Risk Analysis
ArriVent BioPharma, Inc. disclosed 93 risk factors in its most recent earnings report. ArriVent BioPharma, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ArriVent BioPharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $854.91M | -2.85 | -207.18% | ― | -7.27% | -48.89% | |
54 Neutral | $1.22B | -4.08 | -467.49% | ― | 3995.74% | 24.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.04B | -5.71 | -50.26% | ― | ― | 8.22% | |
49 Neutral | $200.90M | -1.19 | -215.23% | ― | 291.42% | 11.70% | |
48 Neutral | $924.78M | -4.26 | -52.89% | ― | ― | 3.56% | |
46 Neutral | $209.22M | -0.90 | -87.95% | ― | -100.00% | 14.08% |
* Healthcare Sector Average
AVBP
ArriVent BioPharma, Inc.
21.00
1.51
7.75%
VSTM
Verastem
10.04
1.32
15.14%
KURA
Kura Oncology
9.61
-1.43
-12.95%
ZNTL
Zentalis Pharmaceuticals
2.21
0.49
28.49%
CGEM
Cullinan Management
14.37
6.31
78.29%
PYXS
Pyxis Oncology
1.68
-1.71
-50.44%
ArriVent BioPharma, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
ArriVent highlights firmonertinib Phase 1b lung cancer data
Positive
Oct 19, 2026
On October 19, 2026, ArriVent BioPharma announced the publication in Cancer Cell of Phase 1b FURTHER trial results for firmonertinib in treatment‑naïve patients with advanced EGFR PACC‑mutant non‑small cell lung cancer. The ...
Business Operations and StrategyProduct-Related Announcements
ArriVent BioPharma Begins U.S. Trial of ARR-002
Positive
Oct 13, 2026
On October 12, 2026, ArriVent BioPharma reported dosing the first U.S. patient in a Phase 1 trial of ARR-002, a potential first-in-class tetravalent antibody-drug conjugate that simultaneously targets MUC16 and NaPi2b in ovarian and endometrial ca...
Business Operations and StrategyProduct-Related Announcements
ArriVent’s FURVENT Phase 3 Trial Misses Primary Endpoint
Negative
Oct 6, 2026
On October 6, 2026, ArriVent reported that its global Phase 3 FURVENT trial of firmonertinib as a first-line monotherapy for EGFR exon 20 insertion mutant non-squamous NSCLC failed to meet its primary endpoint of progression-free survival by blind...
Business Operations and StrategyFinancial Disclosures
ArriVent inks China partnership for ARR-002 development
Positive
Aug 12, 2026
On August 11, 2026, ArriVent BioPharma entered into an exclusive collaboration and license agreement with Shanghai Allist Pharmaceuticals, granting Allist rights to research, develop, manufacture and commercialize ARR-002 in Greater China while re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.